Neurocognitive functioning and facial affect recognition in treatment-resistant schizophrenia treated with clozapine.

Can antipsychotics improve social cognition in patients with schizophrenia? CNS Drugs (2013) 0.79

The Change in Facial Emotion Recognition Ability in Inpatients with Treatment Resistant Schizophrenia After Electroconvulsive Therapy. Psychiatr Q (2017) 0.75

Cavum septum pellucidum and adhesio interthalamica in schizophrenia: an MRI study. Eur Psychiatry (2006) 1.54

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology (2011) 1.41

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol (2010) 1.31

Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology (2004) 1.10

Interaction between cannabidiol (CBD) and ∆(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology (Berl) (2011) 0.90

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr (2012) 0.89

Electromyographic evaluation in children having rapid maxillary expansion. Am J Orthod Dentofacial Orthop (2009) 0.88

The effect of age on the function of the masticatory system--an electromyographical analysis. Gerodontology (2006) 0.85

[Pharmacological treatment of psychosis in epilepsy]. Rev Bras Psiquiatr (2004) 0.83

The fast alcohol screening test (FAST) is as good as the AUDIT to screen alcohol use disorders. Subst Use Misuse (2010) 0.81

Association between spinocerebellar ataxias caused by glutamine expansion and psychiatric and neuropsychological signals - a literature review. Am J Neurodegener Dis (2013) 0.79

Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology (2011) 0.79

Electromyographic analysis of the orbicularis oris muscle in oralized deaf individuals. Braz Dent J (2006) 0.78

Total agenesis of the corpus callosum in a patient with childhood-onset schizophrenia. Arq Neuropsiquiatr (2007) 0.78

NMDA and AMPA/kainate glutamatergic receptors in the prelimbic medial prefrontal cortex modulate the elaborated defensive behavior and innate fear-induced antinociception elicited by GABAA receptor blockade in the medial hypothalamus. Cereb Cortex (2013) 0.77

Electrodermically nonresponsive schizophrenia patients make more errors in the Stroop Color Word Test, indicating selective attention deficit. Schizophr Bull (2002) 0.77

Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis. CNS Neurol Disord Drug Targets (2015) 0.77

Human experimental anxiety: actual public speaking induces more intense physiological responses than simulated public speaking. Rev Bras Psiquiatr (2013) 0.76

Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection. Mol Neurobiol (2013) 0.76

Involvement of prelimbic medial prefrontal cortex in panic-like elaborated defensive behaviour and innate fear-induced antinociception elicited by GABAA receptor blockade in the dorsomedial and ventromedial hypothalamic nuclei: role of the endocannabinoid CB1 receptor. Int J Neuropsychopharmacol (2013) 0.76

Proton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the methodology. Rev Hosp Clin Fac Med Sao Paulo (2004) 0.76

Accuracy of psychiatric diagnosis performed under indirect supervision. Rev Bras Psiquiatr (2005) 0.75

[A comparison of consultative psychiatric services in two Brazilian university hospitals using a standardized protocol for recording liaison consultations]. Cad Saude Publica (2010) 0.75

No association between electrodermal hyporesponsivity and enlarged cavum septi pellucidi in schizophrenia. Schizophr Res (2007) 0.75

Olanzapine for recurrent excessive irritability and psychotic symptoms after mesial temporal lobectomy in a patient with temporal lobe epilepsy. Epilepsy Behav (2006) 0.75

Validation of the Subjective Handicap of Epilepsy (SHE) in Brazilian patients with epilepsy. Epilepsy Behav (2012) 0.75

Neurobiological substrates of electroconvulsive therapy for Tourette syndrome: a Serial SISCOM study. J ECT (2007) 0.75

An Overview on the Search for Schizophrenia Biomarkers. CNS Neurol Disord Drug Targets (2015) 0.75

Paliperidone palmitate for refractory and clozapine-resistant schizophrenia. J Neuropsychiatry Clin Neurosci (2014) 0.75

Disorganized Symptoms Predicted Worse Functioning Outcome in Schizophrenia Patients with Established Illness. Clin Schizophr Relat Psychoses (2015) 0.75